Elective & STP advice

Elective: From conception to cradle

Samantha Horridge Clinical Scientist (Microbiology) 18.12.17

Learning outcomes

- To gain more knowledge and understanding of infections during and post-pregnancy (RFH)
- To carry out **audit** and educational training on Group B Streptococcus to Obs, Gynae and Micro
- To understand the effect and management of infections in **neonates** (GOSH)
- To observe in sexual health clinical the presentations of common **STIs** and POCT and so laboratory role at the front line (Marlborough)

Good Scientific Practice (AHCS)

Professional Practice

Probity, Working with Colleagues, Training and developing others

Scientific Practice

Scientific Practice, Technical Practice, Quality

Clinical Practice

- Clinical Practice, Investigation and Reporting
- Research, Development and Innovation
- Clinical Leadership

Maternity, Labour & Antenatal

- Antenatal clinics & Ward rounds with doctors (Labour and Antenatal)
 - UTI
 - Thrush, BV
 - STI incl. HIV
 - GBS
 - Infected scars
 - Sepsis
 - Anaemia, Endometriosis, Miscarriage, Still birth, Mental health problems, Asthma
 - C-section

Clinical case

- 34 yr old Female, 28/40
- PMH: sickle cell, ectopic pregnancy, History of endometriosis & Herpes Simplex Virus
- This pregnancy: Thrush, UTI, slightly low haemoglobin, recurrent herpes, pericardial effusion (baby) on scan
- Management: Trx of UTI/Thrush where appropriate, prophylaxis for Herpes nearer term

Marlborough Clinic (Sexual Health)

Consultations

- Routine check up
- Symptoms
- Contraception advice
- Pregnancy
- Contact
- Examinations
 - Symptoms (pain, warts, discharge)
- Hot lab
 - BV, TV, Thrush, Gonorrhoea, pregnancy test, HIV POCT

Clinical case

- 22 year old male and female in relationship
- Consultation: Asked about past infections (M=Chlamydia 4 yrs ago), symptoms (N) and sexual history for last 3/52
- No examination as asymptomatic
- Samples: Urine (M), swab (F)
- Results: Chlamydia postive both
- Health care advisor consultation: Explanation on Chlamydia and that it has come from F
- Treatment: Both stat dose Azithromycin

ICDC Clinical case

- 45 year old MSM, HIV positive, Chlamydia contact 1 month ago. Since then 3 other sexual partners, all UPAI, CMP with patient being the active partner. No oral sex.
- Investigations: Swabs and examination
- Results: CT, GC negative, syphilis positive
- Treatment: Azithromycin 1g stat dose-4 tablets taken orally in one dose. Cryotherapy performed on anal warts. Both given and done at consultation.
- Follow-up: As syphilis was detected patient will need to return to clinic to be treated with IM benzathine penicillin G and will need to contact the 4 sexual contacts mentioned for them to be treated and tested too.
- Social problem of partner notification highlighted

Reflective

- Sensitive nature of healthcare issues related to these high-risk groups
- Vast amount of people involved in patient care
- Impact that lab results have on patient management
- Difficult situations
- Out of comfort zone
- Lucky to have opportunity
- Highlighted education

How experience will shape future practice?

- Keep up to date with changes in vaccines or management strategies for infections in pregnancy
- Will allow me to re-audit with people I have built up good relations with
- Re-emphasised to me particular areas of interest
- Remind oneself of clinical impact and individual patient when processing samples in laboratory
- Critical thinking on education/audits and laboratory procedures

GBS audit

- Confusion over when to 'screen', what samples to take and subjectivity with regards to following guidelines on when to take samples and/or give IAP.
- Lab results Oct 2012-Oct 2013
- 44 questionnaires



Group B Streptococcus

My name is Samantha Horridge and Lama Trainee Clinical Scientist from microbiology conducting a naudit projections ampling for GBS in pregnant women and the guidelines related to this.

Lamidistributing this questionnaire to staff in Obstetrics and Gyraecology (wards, clinics and community). and Microbiology (laboratory and medics) to investigate current knowledge and whether practice is following current guidelines.

Arswers given will remain anonymous.					
I would greatly appreciate your time to fill in this brief Questionnaire,					
Thank you					
1. From evidence, what percentage of women are thought to be colonised with GES in their genital tract?					

	-	>60%
2.	Fr	om which site(s) is/are sample (s) taken for optimum detection of GBS in pregnant women?
	Yo	ou may choose more than one:

- LVS
- Endocervical
- Vaginal

- <15% - 15-30% 30-45% 45-60%

Rectal

- HVS

- Urine

3.	In what circumstances would you take a genital (HVS, LVS, Endocervical etc.) swab from a pregnant woman?
4.	In what droumstances would you take a sample to specifically test for GES in a pregnant woman?



	NHS Foundation Trust
5. I	f pregnant woman, 20 weeks into pregnancy, is incidentally found to be colonised with GES but
i	s completely asymptomatic, would you treat?
-	Yes
-	No
	f a pregnant woman is found to have an infection where GBS may be the cause, would you reat?
-	Yes
-	No
	n what droumstances would intrapartum prophylaxis (IAP) be given? You m ay select more han one:
-	To a known GBS colonised woman in labour
	To a woman with feverduring labour
-	To a woman who has had G 85 found in urine during pregnancy
8. /	and with regards to second pregnancies?You may select more than one:
-	To a woman giving birth to second child where in the infirst pregnancy they were GBS colonised
-	To a woman giving birth to second child where in first pregnancy the child developed Group B neonatal seps is
-	To a woman who has had a infection which may have been attributable to GBS during her pregnancy
9. 1	What is the biggest concern regarding a woman with GBS in labour?
-	The reonate developing early onset sepsis
-	The neonate developing late onsetseps is
-	Me ning itis
-	Woman getting ill post-delivery
-	Stillbirth of baby

Questions

- o % of women colonised with GBS?
- Optimum sites to take samples from?
- Circumstances where you would take a sample from a pregnant woman?
- Circumstances where you would take a sample specifically for GBS?
- Treatment (symptomatic and asymptomatic women)?
- Intrapartum prophylaxis?
- o Main concern with GBS infection in neonate?

Summary of findings:

- Midwives and Drs believed higher % of women were colonised
- Discrepancies with what site to swab
- Most knew when to use prophylaxis
- Most recognised EOGBS as the biggest concern
- Midwives tended to give wide range of answers

Fact sheet

Group B Streptococcus Information Sheet

Screening for GBS: Remains controversial and more evidence is needed.

- From evidence-15-30% of women carry GES in the vagina. Vaginal carriage can be transient, so women previous ly found to be colonised may be negative when retested at a later date and other previous ly negative women may be found to be positive. Of those colonised at the time of labour, 50-70% will pass GES onto the neonate, but only 1% (according to LeDoare & Heath, 2013) of these colonised babies will develop GES disease. There are certain risk factors where the risk of a baby developing GES disease and the UK currently action these risk factors rather than screening all pregnant women.
- Routine bacteriological screening of all pregnant women for antenatal GBS carriage is not recommended in the UK (RCOG guidance)
- At Royal Free London NHS Foundation Trust we offer screening for women who request it
- A negative screen during pregnancy is not a guarantee that a woman will be negative for GBS during labour. She will still be given intra-partum prophylaxis if she has risk factors (see below)

ntra-partum Antibiatic Prophylaxis (LAP) indications for use (R COG and Rayal Free guidance):

- GBS detected on a vaginal swab in the current pregnancy.
- GBS bacteriuria identified in current pregnancy
- Women with a previous baby affected by neonatal GBS disease
- Women who are pyrexial in labour (>38°C).
 - Women who are pyrexial in labour should be offered broad-spectrum antibiotics including an

ntre-per turn Antibiotic Prophylexis (LAP) NOT indicated (RCDG)

- Women undergoing planned caesarean section in the absence of labour and with intact membranes
- Women presenting in established preterm labour with intact membranes with no other risk factors and no known colonisation
- Women where GBS carriage was detected in a previous pregnancy but baby was not affected
 - o This can be discussed on a case-by-case basis though
- Unclear evidence for women with term pre-labour rupture of membranes



Urine is the most common sample for incidentally finding GBS

Best samples for optimum GBS detection are LVS and Rectal swebs taken at the same time



ntra-partum Antibiatic Prophylaxis (LAP) indications for use (R CDG and Rayal Free guidance):

- GBS detected on a vaginal swab in the current pregnancy.
- GBS bacteriuria identified in current pregnancy
- Women with a previous baby affected by neonatal GBS disease
- Women who are pyrexial in labour (>38°C).
 - Women who are pyrexial in labour should be offered broad-spectrum antibiotics including an

ntre-per turn Antibiotic Prophylexis (LAP) NOT indicated (RCDG)

- Women undergoing planned caesarean section in the absence of labour and with intact membranes
- Women presenting in established preterm labour with intact membranes with no other risk factors and no known colonisation
- Women where GBS carriage was detected in a previous pregnancy but baby was not affected.
 - o. This can be discussed on a case-by-case basis though
- Unclear evidence for women with term pre-labour rupture of membranes

Fact sheet

Guidelines and New testing

From I January 2014, an improved test for Group B Streptococcus is available in Public Health England's Eight Regional Laboratories in England



Group B Streptococcus

GBS (Streptococcus agalactiae) is recognised as the most frequent cause of severe early-onset (age 0-6 days) infection in newborn infants. The incidence of early-onset group B Strep (EOGBS) disease in the UK in 2000 was 0.5/1000 births¹ and reports to the Health Protection Agency of culture proven disease have increased by about 50% over the last decade².

GBS colonises the intestines of many men and women. Up to 30% of women carry GBS in the vagina or rectum without it causing problems or symptoms^{3,4}. Carrier status is best identified by LOW VAGINAL and RECTAL swabs (NOT a high vaginal swab).

What culture test should be used?

Currently, most NHS pathology services use culture media which is 'general purpose' and only identifies GBS in about 60% of carriers. At the request of the Chief Medical Officer Prof Dame Sally Davies, from 1 January 2014 the 'Enriched Culture Medium' (ECM) test is available throughout England. This will identify about 90% of carriers and is the 'gold standard' for this purpose, using Public Health England's Regional Laboratories' Standard Operating Procedure. The results of this GBS test are about 85% predictive of carriage status for up to 5 weeks⁵ (the shorter the interval since testing, the more likely the status is to remain the same). It should be used whenever there is an indication to identify GBS carriage. Routine screening of all pregnant women is not recommended by the UK National Screening Committee6:

How to test for group B Strep carriage:

When? If there is an indication for GBS testing to predict carriage

status at delivery, the best time to take swabs is between

35-37 weeks of gestation.

Where? Swab the lower vagina (vaginal introitus) and the rectum

with the same swab or two swabs. Women can take these

swabs themselves if they prefer.

How? Use swabs for bacterial culture, then place them in Amies

transport medium with charcoal⁷. Label 'for GBS culture in ECM medium' on the request form.
Your local laboratory will then ensure that the correct test

is done.

What happens next?

The result The result should in most cases be available after 48

hours of culture. It is the responsibility of the health team to ascertain the result, record it in the medical notes, and inform the woman

concerned and her health team.

Negative Inform the pregnant woman and her health team.

Intrapartum antibiotic prophylaxis (IAP) should not be offered unless known risk

factors^{8,9} are present.

Positive Inform the pregnant woman and her health team. No

treatment or prophylaxis is required until the onset of labour. GBS is not a cause of vaginal discharge, although it can cause urine infections. As soon as possible once labour starts, offer the mother intrapartum

antibiotic prophylaxis (IAP).

AP Intrapartum antibiotic prophylaxis (IAP) should be offered to the mother as soon as possible once labour has started using Benzylpenicillin^{8,9}. The recommended dosing regimen

alternative.

To achieve optimum efficacy of IAP, the first dose should be

given at least 2 hours before delivery8.

IAP has been shown to reduce the risk of culture-positive early-onset GBS disease by up to 90%¹⁰ (but does not reduce late-onset GBS disease, occurring 7 or more days

after birth).

If chorioamnionitis is suspected, women should be offered broad-spectrum antibiotics⁸ including an antibiotic for prevention of

EOGBS disease.

SCBU/NICU Inform the neonatologist of the mother's GBS carrier

status if there are any neonatal problems.

Limitations/ Problems encountered

- Number of people
- Timing
- Questionnaires
- 'Vaginal swab' should have been excluded as an option for site
- Follow-up of those writing 'Previous GBS'
- Getting information to everyone
- Subjectivity & own judgement
- Re-audit

Acknowledgements

- Dr Robin Smith
- Dr Alison Wright
- Obs & Gynae, Antenatal wards & clinics
- Sarah Edwards & Mirelle Harris
- Marlborough Clinic staff
- Louie Pong
- Owen Billington & Damion Cotterill

STP & HSST

- 0 2011-2014
 - Royal Free Hospital, St Georges, PHE (Colindale)
- 2014-2019
 - UHCW NHS Trust

Advice

- Competencies vs. experience
- Map out and plan your training
- Take and make opportunities
- Respect
- Ask for help

Personal g

GOALS

Short term goals: Gain registration post completion of STP training, settle into new job role

Medium term goals: Be confident in position as band 7 scientist in the laboratory and in liaison role, building good relationships with people in the hospital. Get good amounts of clinical exposure and build on experience and knowledge in giving treatment advice and taking part in multidisciplinary meetings building a thorough record of cases. Balance work and life outside of work well and continue to manage stress effectively so it impacts minimally on job and personal life/health.

Long-term goals: Complete the HSST if I enjoy it and feel it is the right thing for me to continue with and FRCPath part 2. Have an influential role within the laboratory and clinical side of microbiology using effective people skills and a senior/manager position to make a difference to this area of science.

AHCS

Clinical Scientist	Complex scientific and clinical roles. High risk, low volume activities which require highly skilled staff able to exercise clinical judgement about complex facts and clinical situations. Training through Scientist Training Programme (STP)	STP (Scientist Training Programme) – postgraduate degree (Masters-level) with clinical placement
Consultant Clinical Scientist	In-depth, highly complex role. Similar to medical consultant role as requires clinical judgement, scientific expertise, leadership and dealing with uncertainty in direct patient care. Training through Higher Specialist Training (HSST) programme.	HSST (Higher Specialist Scientific Training) at doctorate level

* Career and Training Pathways for the UK Healthcare Science Workforce

Consultant Clinical Scientist Appointment

eligibility to apply for

AHCS PSA Accredited Higher Specialist Scientist Registration

Accredited Additional Scientific Practice (AASP)



AHCS Accredited Registration

Assistant and
Associate Training
Programme [including
apprenticeships]
(AATP)
Level 2 and Level 4
Diploma

Apprenticeship or In-service

Accredited Specialist Scientific Practice (ASSP)

Healthcare Science Practitioner (including Biomedical Scientists)

¹AHCS PSA Accredited Registration and/or ²HCPC Statutory Regulation

Practitioner Training Programme (PTP)

Integrated BSc (Hons)
Healthcare Science

Equivalence

Progression

Route



Apprenticeship, Full-time Student or In-service Accredited Expert Scientific Practice (AESP)

Equivalence

Progression

Route

³Higher Specialist Scientist Training (HSST)



⁴ Clinical Academic Career

Clinical Scientist

HCPC Statutory Regulation

Scientist Training Programme (STP)

Integrated MSc Clinical Science and Workbased Programme



Graduate Direct Entry or In-service * Previously known as: Modernising Scientific Careers: Career and Training Pathways

¹ as a Healthcare Science Practitioner

² as a Biomedical Scientist

³ work-based programme with underpinning DClinSci

4 currently under development

HCPC: Health and Care Professions Council

AHCS: Academy for Healthcare Science

PSA: Professional Standards Authority (accredits AHCS and other workforce Registers)

as of July 2017

Opportunities

- Laboratory
- Development/innovation/improvem ent
- Research/PhD
- Public Health
- Teaching
- Management
- Clinical

Questions and contact details

- Samantha Horridge
- University Hospitals Coventry and Warwickshire NHS Trust
- Samantha.horridge@uhcw.nhs.uk